KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S.

Tamar Kinaciyan, Emel Aygören-Pürsün, Inmaculada Martinez-Saguer, Daniel F Soteres, Daisuke Honda, Michael E Manning, H James Wedner, Atsushi Fukunaga, Henry J Kanarek, Kazumasa Ohmura, Isaac Melamed, Tariq El-Shanawany, Laurence Bouillet, William R Lumry, Marc A Riedl, Majed Koleilat, Bob Geng, Isao Ohsawa, Noemi Bara, Syed Rehman, Jonathan A Bernstein, Paula J Busse, Mauro Cancian, Danny M Cohn, Timothy J Craig, Henriette Farkas, Sorena Kiani-Alikhan, H Henry Li, Jason P Raasch, Raffi Tachdjian, Paul K Audhya, Paolo Bajcic, Ya-Hsiu Chuang, Matthew Iverson, Michael D Smith, Christopher M Yea, Andrea Zanichelli

J Allergy Clin Immunol Glob 5(5) 100750

PMID42436759
PMCIDPMC13355760
DOI10.1016/j.jacig.2026.100750
发表日期2026-07-12
AI 判定该论文不进入自动 KM 提取:This record reports results from an open-label extension study (KONFIDENT-S), not a randomized controlled trial. The abstract explicitly states it is an 'open-label extension study' and describes interim analysis of a long-term safety and effectiveness study, not a phase III RCT.
摘要

摘要

BACKGROUND: Although long-term prophylaxis (LTP) reduces attack frequency in hereditary angioedema, patients may experience breakthrough attacks. Oral sebetralstat demonstrated favorable safety and efficacy compared with placebo in the randomized phase 3 KONFIDENT trial (NCT05259917), including in patients receiving LTP. The safety and effectiveness of sebetralstat in participants receiving LTP are being assessed in the KONFIDENT-S open-label extension study (NCT05505916). OBJECTIVE: This interim analysis of the KONFIDENT-S study evaluated long-term safety and effectiveness of oral sebetralstat 600 mg for attacks of hereditary angioedema with C1-inhibitor deficiency in participants receiving LTP with lanadelumab, berotralstat, or C1 inhibitor. METHODS: Efficacy end points included times to beginning of symptom relief, reduction in severity, and complete attack resolution. RESULTS: As of September 14, 2024, 35 participants receiving LTP experienced a mean ± standard deviation of 1.7 ± 1.5 attacks per month and treated 382 attacks with sebetralstat (1.3 ± 1.1 sebetralstat-treated attacks per month). Median (interquartile range) time from attack recognition to sebetralstat administration was 6 (1-40) minutes; time to beginning of symptom relief was 1.3 (0.8 to 3.8) hours, time to reduction in severity was 4.2 (1.3 to >12) hours, and time to complete attack resolution was 14.8 (4.6 to >24) hours. Effectiveness was similar for participants receiving berotralstat, lanadelumab, or C1 inhibitor. No serious or severe treatment-related treatment-emergent adverse events were reported. CONCLUSION: Sebetralstat was well tolerated and enabled early on-demand treatment of attacks in patients with hereditary angioedema with C1-inhibitor deficiency receiving LTP. Treatment of breakthrough attacks with sebetralstat resulted in rapid symptom relief, reduction in attack severity, and complete attack resolution, regardless of LTP mechanism of action.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。